Oyster Point Pharma, Inc. price (OYST)

About Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.